Search filters
Update TerugBetaalRegeling Veltassa®, patiromer 8.4g

Update TerugBetaalRegeling Veltassa®, patiromer 8.4g

01/05/2023

From May 1, 2023, the use of Veltassa® 8.4g will be fully reimbursed by the health insurer. For this reason the Reimbursement...

Update Reimbursement Scheme Jardiance®

Update Reimbursement Scheme Jardiance®

01/04/2023

From April 1, 2023, the use of Jardiance® (empagliflozin) in patients with chronic heart failure regardless of ejection fraction...

Update Reimbursement Fludrace®

Update Reimbursement Fludrace®

30/03/2023

The existing TBR for Fludrace® 62.50 micrograms has been expanded with the strength 31.25 micrograms. Because the health insurer...

Reimbursement Scheme Acecort®

Reimbursement Scheme Acecort®

27/02/2023

The health insurer fully reimburses Acecort® 1, 2 and 3 mg as off March 1, 2023. The reimbursement by TBR Nederland will therefore...

Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg for the treatment of HFpEF (LVEF >40%)

Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg for the treatment of HFpEF (LVEF >40%)

27/02/2023

The health insurer does not yet fully reimburse Forxiga® (dapagliflozin) 10 mg for the treatment of HFpEF (LVEF >40%). The...

You are currently offline. Some pages or content may fail to load.